<DOC>
	<DOCNO>NCT01966900</DOCNO>
	<brief_summary>The potential HIV vaccine two component : protein immunogen base coat protein HIV ; adjuvant enhances vaccinee 's response immunogen . The immunogen CN54gp140 , adjuvant glucopyranosyl lipid adjuvant - aqueous formulation ( GLA-AF ) . We wish assess vaccine 's safety immunogenicity ( nature immune response stimulate vaccine ) give two different dose regimen : Group A : vaccination Months 0 , 1 , 2 6; Group B : vaccination Months 0 , 1 , 2 12 . Each dose intramuscular injection 100 microgram CN54gp140 mix 5 microgram GLA-AF . We recruit healthy , HIV-uninfected men woman . We assess safety vaccine monitoring occurrence adverse event participant . We assess immunogenicity vaccine monitor immune response vaccine blood genital mucosal secretion sample .</brief_summary>
	<brief_title>The Safety Immunogenicity Potential HIV Vaccine</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female , assess medical history , physical exam , laboratory test ; At least 18 year age day screen reach his/her 46th birthday day first vaccination ; Willing comply requirement protocol available followup plan duration study ; Willing able give write informed consent ; Willing undergo HIV testing , receive HIV test result commit maintain low risk behaviour trial duration ; If female sexually active male partner ( ) , willing use effective method contraception screen least 4 month last study vaccination [ e.g. , hormonal contraceptive , consistent record condom , physiological anatomical sterility self partner , exclude intrauterine device ( IUD ) would preclude collection cervicovaginal secretion Softcup ] ; All female volunteer must willing undergo urine pregnancy test time point indicate Schedule Procedures ( Appendices AB ) must test negative prior study vaccination ; All sexually active male ( unless anatomically sterile monogamous relationship female partner us document nonbarrier method birth control ) must willing use effective method contraception ( e.g. , consistent condom use ) day first vaccination least 4 month last vaccination ; Willing forgo donation blood tissue study , test HIVpositive due trial vaccination ( vaccineinduced HIV seropositivity ) , antiHIV antibody titres become undetectable . Registered general practitioner least past three month Confirmed HIV1 HIV2 infection ; Any clinically relevant abnormality history examination include history immunodeficiency autoimmune disease ; use systemic corticosteroid ( use topical inhaled steroid permit ) ; immunosuppressive , anticancer , antituberculosis medication consider significant investigator within previous 6 month ; Any clinically significant acute chronic medical condition consider progressive , opinion investigator , make volunteer unsuitable participation study ; Reported risky behaviour HIV infection within 6 month prior vaccination define : history inject drug use previous ten year ; gonorrhoea syphilis last six month ; high risk partner ( e.g . inject drug use , HIV positive partner ) either currently within past six month ; unprotected anal intercourse last six month , outside relationship regular partner know HIV negative ; unprotected vaginal intercourse last six month outside relationship regular known/presumed HIV negative partner . Reported abnormal cervical cytology previous ongoing treatment Cervical Intraepithelial Neoplasia ; If female , pregnant planning pregnancy within 4 month last study vaccination ; lactating ; Bleeding disorder diagnose physician ( e.g. , factor deficiency , coagulopathy platelet disorder require special precaution ) ( Note : A volunteer state easy bruise bleeding , formal diagnosis intramuscular injection blood draw without adverse experience , eligible ) ; History splenectomy ; Any follow abnormal laboratory parameter list : haemoglobin &lt; 11.0 g/dL ; absolute neutrophil count ( ANC ) ≤ 1.3 x 109/L ; absolute lymphocyte count ( ALC ) ≤ 0.9 x 109/L ; platelet ≤ 125 x 109/L ; creatinine &gt; 1.1 x upper limit normal ( ULN ) ; aspartate aminotransferase &gt; 1.25 x ULN ; alanine aminotransferase &gt; 1.25 x ULN ; clinically significant abnormal urinalysis dipstick confirm microscopy ( protein 2+ , blood 2+ due menses ) ; positive hepatitis B surface antigen ( HbsAg ) , hepatitis C ( HCV antibody ) active syphilis ; Receipt liveattenuated vaccine within previous 60 day plan receipt within 60 day vaccination Investigational Product ; receipt vaccine , allergy treatment antigen injection tuberculin skin test within previous 14 day plan receipt within 14 day vaccination Investigational Product ; Receipt blood transfusion bloodderived product within previous 3 month ; Participation another clinical trial Investigational Product currently , within previous 3 month expect participation study ; Prior receipt another investigational HIV vaccine candidate ( Note : receipt placebo previous HIV vaccine trial exclude volunteer participation documentation available ) ; History severe local systemic reactogenicity vaccine ( e.g. , anaphylaxis , respiratory difficulty , angioedema ) ; Psychiatric condition compromise safety volunteer precludes compliance protocol . Specifically excluded person psychosis within past 3 year , ongoing risk suicide , history suicide attempt gesture within past 3 year ; Seizure disorder : participant seizure last 3 year exclude . ( Not exclude : participant history seizures neither required medication seizure 3 year . ) ; If female , history toxic shock syndrome ( TSS ) , would preclude use Softcup ; If female , current use intrauterine device ( IUD ) , would preclude use Softcup ; If , opinion Principal Investigator , best interest volunteer participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Human immunodeficiency disease</keyword>
	<keyword>HIV</keyword>
	<keyword>Vaccine</keyword>
	<keyword>CN54gp140</keyword>
	<keyword>Glucopyranosyl lipid adjuvant</keyword>
	<keyword>GLA</keyword>
	<keyword>GLA-AF</keyword>
</DOC>